WESTLAKE VILLAGE, Calif., May 16, 2018 (GLOBE NEWSWIRE) — Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that pre-clinical data from the Company’s topical product candidate SNA-125, a novel, selective kinase inhibitor currently in Phase 1/2 proof-of-concept clinical trials for psoriasis and atopic dermatitis, will be presented as a Late-Breaking Poster, entitled, “SNA-125, a Novel Selective Kinase Inhibitor, Improves Clinical Symptoms in a Mouse Model of Psoriasis,” on Thursday, May 17, 2018, between 11:45 a.m. and 1:45 p.m. ET, at International Investigative Dermatology 2018 in Orlando, Fla.
SNA-125 is Sienna’s second unique drug candidate created from the Company’s proprietary Topical by Design™ technology, which optimizes small molecules for topical administration, balancing the benefits of high local drug concentration with low systemic exposure.
In February 2018, Sienna announced that the first patient had been dosed with SNA-125 in a first-in-human, Phase 1/2 proof-of-concept clinical trial for psoriasis. Data are expected in the third quarter of 2018. SNA-125 is also being studied in a Phase 1/2 proof-of-concept clinical trial for atopic dermatitis, with data expected in the fourth quarter of 2018.
SNA-125 is a selective kinase inhibitor that inhibits Janus kinase 3, or JAK3, and tropomyosin receptor kinase A, or TrkA. JAK3 is required for immune cell development, and inhibiting JAK3 blocks the signaling of key cytokines, such as interleukin-2, or IL-2, IL-4, IL-17A, IL-17F and tumor necrosis factor-alpha, or TNF-α, in T cells and NK cells, and results in a reduction in the severity of autoimmune and inflammatory diseases in which those cytokines play a pivotal role. JAK3 is a validated target in psoriasis, atopic dermatitis and pruritus. TrkA is the high affinity receptor for nerve growth factor, or NGF, a known mediator of neurogenic inflammation and itch associated with psoriasis.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The Company’s objective is to develop an innovative, diversified, multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology and aesthetics patients. Sienna is led by a management team with extensive experience in product development and commercialization at several leading dermatology, aesthetics and biotechnology companies. For more information, visit the Company’s website at www.SiennaBio.com.
This press release contains forward-looking statements, including but not limited to statements regarding the timing of data readouts from Sienna’s Phase 1/2 proof-of-concept clinical trials of SNA-125. Such forward-looking statements involve substantial risks and uncertainties that could cause Sienna’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the clinical trial enrollment process, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Sienna’s ability to successfully protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations and the availability or commercial potential of Sienna’s product candidates. Sienna undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see Sienna’s most recent Quarterly Report on Form 10-Q and any subsequent current and periodic reports filed with the Securities and Exchange Commission.
Sean Andrews (Investors)
Crystal Muilenburg (Media)